A final guidance document has been issued by the National Institute for Health and Care Excellence recommending the 16-week use of AbbVie's Humira, or adalimumab, and Janssen's Stelara, or ustekinumab, as options for treating plaque psoriasis in children and young people whose disease is severe, who cannot use other treatments or who have not improved with the use of other treatments. NICE also backed the use of Pfizer's Enbrel, or etanercept, for 12 weeks for the same indication.
Plaque psoriasis drugs from AbbVie, Pfizer, Janssen recommended by NICE
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.